Cytokinetics Revolutionizes the Treatment of Heart Muscle Diseases – Aficamten Is a $3.4 Billion Opportunity!
Reading Time: 2 minutes
Cytokinetics (CYTK) specializes in developing innovative therapies for treating heart muscle diseases and aims to reach over 100,000 patients worldwide with its pipeline by 2030. A significant step towards the first FDA product approval is the data presented from the Phase 3 study MAPLE-HCM, which showed that the promising candidate Aficamten is superior to beta-blockers that have been used for over 60 years in treating obstructive hypertrophic cardiomyopathy (oHCM). oHCM is a genetically inherited heart disease in which the heart muscle is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
